Search hospitals > Louisiana > Metairie
LSU Healthcare Network / Metairie Multi-Specialty Clinic
Claim this profileMetairie, Louisiana 70006
Global Leader in Skin Cancer
Global Leader in Prostate Cancer
Conducts research for Bladder Cancer
Conducts research for Kidney Cancer
Conducts research for Transitional Cell Carcinoma
39 reported clinical trials
7 medical researchers
Summary
LSU Healthcare Network / Metairie Multi-Specialty Clinic is a medical facility located in Metairie, Louisiana. This center is recognized for care of Skin Cancer, Prostate Cancer, Bladder Cancer, Kidney Cancer, Transitional Cell Carcinoma and other specialties. LSU Healthcare Network / Metairie Multi-Specialty Clinic is involved with conducting 39 clinical trials across 143 conditions. There are 7 research doctors associated with this hospital, such as Scott E. Delacroix, Augusto C. Ochoa, Amelia Jernigan, MD, and Rajasree P. Chowdry.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage I
Stage II
2Prostate Cancer
Global LeaderStage IV
PD-L1 positive
BRCA1 positive
Top PIs
Scott E. DelacroixLSU Healthcare Network / Metairie Multi-Specialty Clinic2 years of reported clinical research
Expert in Prostate Cancer
Expert in Skin Cancer
28 reported clinical trials
63 drugs studied
Augusto C. OchoaGulfport Memorial Hospital7 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
16 reported clinical trials
71 drugs studied
Amelia Jernigan, MDUniversity Medical Center New Orleans1 year of reported clinical research
Studies Ovarian Cancer
Studies Cancer
8 reported clinical trials
19 drugs studied
Rajasree P. ChowdryUniversity Medical Center New Orleans1 year of reported clinical research
Studies Cancer
Studies Kidney Cancer
5 reported clinical trials
16 drugs studied
Clinical Trials running at LSU Healthcare Network / Metairie Multi-Specialty Clinic
Prostate Cancer
Bladder Cancer
Kidney Cancer
Bladder Carcinoma
Skin Cancer
Ovarian Cancer
Prostate Adenocarcinoma
Renal Cell Carcinoma
Kidney Carcinoma
Fallopian Tube Cancer
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at LSU Healthcare Network / Metairie Multi-Specialty Clinic?
LSU Healthcare Network / Metairie Multi-Specialty Clinic is a medical facility located in Metairie, Louisiana. This center is recognized for care of Skin Cancer, Prostate Cancer, Bladder Cancer, Kidney Cancer, Transitional Cell Carcinoma and other specialties. LSU Healthcare Network / Metairie Multi-Specialty Clinic is involved with conducting 39 clinical trials across 143 conditions. There are 7 research doctors associated with this hospital, such as Scott E. Delacroix, Augusto C. Ochoa, Amelia Jernigan, MD, and Rajasree P. Chowdry.